The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare effects of 52 weeks' treatment with either raloxifene 60 mg/day alone (RLX) or in combination with 17beta-estradiol 1 mg/day (RLX + E) on vasomotor symptoms (n = 83) and endometrial safety (n = 123) in postmenopausal women who transitioned from estrogen-progestin therapy. DESIGN: In this randomized, double-blind clinical trial, the frequency of vasomotor symptoms, hot flashes, and night sweats was assessed for up to 52 weeks. Endometrial thickness was assessed by transvaginal ultrasonography at baseline and at 12 and 52 weeks. An exit endometrial biopsy was performed at study completion or early termination. RESULTS: The frequency of vasomotor symptoms, hot flashes, and night sweats was unchanged from baseline with RLX but was significantly reduced in women treated with RLX + E, from baseline (all P < 0.001) and the RLX group at 6, 12, 24, 36, and 52 weeks (all P < 0.01). Women in the RLX + E group had significantly increased endometrial thickness (0.74 +/- 0.28 mm, mean +/- SEM) at 52 weeks, from baseline and RLX (P < 0.05), with no statistically significant changes in women treated with RLX. Two women, both in the RLX + E group, had endometrial hyperplasia (one with atypia) on the exit biopsy. CONCLUSIONS: In women transitioning from estrogen-progestin therapy, occurrence of vasomotor symptoms was unchanged from baseline with RLX treatment, but these symptoms were significantly reduced with combined RLX + E therapy. Signs of endometrial stimulation were observed in the RLX + E group. Further studies using different estrogen doses and preparations are needed before concomitant use of raloxifene with systemic estrogens can be recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martino, S., Cauley, J. A., Barrett-Connor, E., Powles, T. J., Mershon, J., Disch, D., Secrest, R. J., Cummings, S. R., & For the CORE Investigators (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh319 · Cited by 684
Commonly Used Types of Postmenopausal Estrogen for Treatment of Hot Flashes: Scientific Review
Nelson, H. D. (2004) · JAMA · doi:10.1001/jama.291.13.1610 · Cited by 296 · cited 1×
“625 mg/day dose of conjugated equine estrogens for treatment of hot flashes.(20)”
Cited by
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
“In two clinical trials, vaginal, but not oral (301) ET, was safely used to treat vaginal symptoms in women taking raloxifene without untoward endometrial effects (302, 303).”
MethodEffects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women
Mirkin, S., Komm, B. S., Pan, K., & Chines, A. A. (2013) · Climacteric · doi:10.3109/13697137.2012.717994 · Cited by 83
Naqvi, H., Sakr, S., Presti, T., Krikun, G., Komm, B., & Taylor, H. S. (2014) · Biology of Reproduction · doi:10.1095/biolreprod.113.114165 · Cited by 54
Metadata
- Authors
- Stovall, D. W., Utian, W. H., Gass, M. L. S., Qu, Y., Muram, D., Wong, M., & Plouffe, L.
- Venue
- Menopause
- Published
- 2007-05
- Volume
- 14
- Issue
- 3
- Pages
- 510-517
- ISSN
- 1072-3714 (ISSN-L)
- OpenAlex
- W2020476951
- Cited by
- 91
- References
- 3
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. https://app.cochat.ai/papers/10.1097/gme.0b013e318031a83d
- The paper
- Stovall, D. W., Utian, W. H., Gass, M. L. S., Qu, Y., Muram, D., Wong, M., & Plouffe, L. (2007). The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause. https://doi.org/10.1097/gme.0b013e318031a83d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.